To include your compound in the COVID-19 Resource Center, submit it here.

Crossovers pile into new rounds for C4, 4D Molecular

Protein degradation company C4 and gene therapy play 4D Molecular each raised venture rounds that included crossover investors, suggesting each company could soon join an IPO queue that has burgeoned in recent weeks. 4D had sought a listing last fall, when it filed an IPO prospectus

Read the full 468 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers